Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
In 2017, liraglutide became the first GLP-1 receptor agonist approved by the FDA to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on results from the LEADER trial
Curr Opin Pharmacol 7, 398403 (2007)
[1] [3] It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now used for chronic weight management following NICE guidance and MHRA approval
Your provider may consider switching to alternative GLP-1 receptor agonists or other medication classes, or referring you to an endocrinologist or obesity medicine specialist for comprehensive management
